Primary Outcomes:

Primary Outcome 1 - Measure: To evaluate the preliminary efficacy of the 2 combinations (Sym021+Sym022 and Sym021+Sym023) in each tumor type under study by assessing ORRs per Investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Primary Outcome 1 - Time Frame: Until disease progression or end of study, whichever comes first, assessed up to 24 months

Primary Outcome 2 - Measure: To evaluate the incidence, severity, and relationship of (S)AEs collected from administration of the first dose of study drug until 30 days after the last dose of the 2 combinations (Sym021+Sym022 and Sym021+Sym023)

Primary Outcome 2 - Time Frame: Through study completion up to 30 days after last dose of the two combinations

Primary Outcome 3 - Measure: To evaluate the AEs leading to dose interruption, dose delays, and permanent treatment stop of the 2 combinations (Sym021+Sym022 and Sym021+Sym023)

Primary Outcome 3 - Time Frame: Through study completion up to a maximum of 12 months

Condition:

• Metastatic Cancer
• Solid Tumor

Eligibility

Criteria:
Inclusion Criteria:

Patients must meet all the following criteria to be eligible for participation in the
study:

- Male or female patients, ≥18 years.

- Patients with documented (histologically or cytologically proven) unresectable,
locally advanced, or metastatic malignancies:

1. Urothelial cancer (UC)

2. Small cell lung cancer (SCLC)

3. Endometrial cancer (EC) of any histological subtype

4. Cholangiocarcinoma (CCA): unresectable or metastatic adenocarcinoma of the intra-
and/or extra-hepatic bile ducts

- Patients with UC, SCLC, and EC must have received prior anti-PD-(L)1 therapy with a
best response of CR/PR or durable SD

- Patients with measurable disease according to RECIST v1.1

- Patients with an ECOG PS of 0 or 1, and anticipated life expectancy of ≥3 months

- Patients must have adequate organ function as indicated by laboratory values

- Adequate contraception required as appropriate

Exclusion Criteria:

- Has central nervous system (CNS) malignancies

- Patients with significant cardiovascular disease

- Patients with

1. Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism,
within 4 weeks prior to the first study drug dose

2. Active uncontrolled bleeding or a known bleeding diathesis

- Patients with a significant pulmonary disease or condition

- Patients with a current or recent (within 6 months) significant gastrointestinal
disease or condition

- Patients with a significant ocular disease or condition

- Patients with an active, known or suspected autoimmune disease

- Patients with any other serious/active/uncontrolled infection

- Prior therapy with anti-LAG-3 or anti-TIM-3 or combinations of these 2 antibodies with
anti-PD-(L)1 antibody or with any other systemic or localized therapy

- Patients with a history of significant toxicities associated with previous
administration of immune checkpoint inhibitors that necessitated permanent
discontinuation of that therapy

- Patients with a known or suspected hypersensitivity to any of the excipients of
formulated study drug

- Patients with unresolved >Grade 1 toxicity associated with any prior antineoplastic
therapy
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No